Cohort for patients with psoriatic arthritis
French Cohort on the Becoming of Recent Articular Psoriatic Rheumatism (A Psoriatic Arthritis CoHort)
This study is tracking 425 patients with their first signs of psoriatic arthritis over 10 years to see what factors lead to more severe disease and how to improve early treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 425 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | methotrexate, prednisone |
| Locations | 3 sites (Créteil and 2 other locations) |
| Trial ID | NCT03768271 on ClinicalTrials.gov |
What this trial studies
The APACHE Cohort is a prospective national multicenter study that aims to follow patients with their first episode of peripheral arthritis attributed to psoriatic arthritis over a period of 10 years. The study will include 425 patients and will collect a variety of clinical data, patient-reported outcomes, and imaging results through standardized visits. The goal is to identify factors associated with aggressive disease patterns and to improve early treatment strategies. This observational study will not involve any therapeutic interventions but will provide valuable data for future research.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 60 who have experienced their first episode of peripheral arthritis in the past year and have a diagnosis of psoriasis or a family history of psoriatic arthritis.
Not a fit: Patients with a formal diagnosis of inflammatory rheumatism other than psoriatic arthritis or those who have received certain treatments for psoriatic arthritis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better early identification and management of patients at risk for severe joint damage due to psoriatic arthritis.
How similar studies have performed: While there have been studies on psoriatic arthritis, this cohort approach focusing on early identification and long-term follow-up is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women or men aged from 18 to 65 inclusive * First episode of peripheral arthritis in the last 12 months, authenticated by a rheumatologist * Psoriasis diagnosed by a practitioner or family history of psoriatic arthritis (first-degree relative \[parent or sibling\] or second degree relative) * Arthritis most likely recognized as a psoriatic arthritis by a rheumatologist (diagnostic confidence score : ≥ 7 out of 10) * Signed informed consent form * Affiliation to a social security system Exclusion Criteria: * Formal diagnostic of inflammatory rheumatism other than psoriatic arthritis * Treatment or history of treatment with a biomedicine * Patient receiving csDMARDS (methotrexate, sulfasalazine, or leflunomide) or apremilast treatment over the past year for rheumatological symptoms * Oral steroids in the last 4 weeks, above 10 mg/d of prednisone or with modified dosage * intravenous or intra articular steroids in the last 4 weeks * IRM contraindication * Cognitive, mental or psychic disorders impeding protocol accomplishment * Difficulties with French language understanding * Patient under tutorship or curatorship * Pregnancy
Where this trial is running
Créteil and 2 other locations
- Henri-Mondor Hospital — Créteil, France (Recruiting)
- Lapeyronie Hospital — Montpellier, France (Recruiting)
- Saint Joseph Hospital — Paris, France (Recruiting)
Study contacts
- Study coordinator: Pascal CLAUDEPIERRE, PHD
- Email: pascal.claudepierre@aphp.fr
- Phone: 01 49 81 47 04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.